WT
ITCI

Whittier Trust’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Whittier Trust’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-216
Closed -$2K – 1627
2019
Q3 		$2K Buy
+216
New +$2.07K ﹤0.01% 1403

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Whittier Trust's ITCI Position: Q4 2019 in Review

Whittier Trust sold out of Intra-Cellular Therapies Inc. (ITCI) in Q4 2019, closing a stake of 216 shares — an estimated $2K sold.

Whittier Trust first reported a position in ITCI in Q3 2019 and held it in 1 quarter. The position peaked at $2K in Q3 2019. 133 funds tracked by Wall St. Rank hold ITCI as of Q4 2019.

  • Whittier Trust reported no remaining Intra-Cellular Therapies Inc. position as of Q4 2019 after selling out during the quarter.
  • Whittier Trust sold 216 Intra-Cellular Therapies Inc. shares in Q4 2019, an estimated $2K.
  • Whittier Trust first reported a position in Intra-Cellular Therapies Inc. in Q3 2019 and held it in 1 quarter.
  • Whittier Trust's Intra-Cellular Therapies Inc. position peaked at $2K in Q3 2019.
  • 133 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q4 2019.

Based on Whittier Trust's 13F filing for Q4 2019, filed 31 Jan 2020.